Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug ...

Trodelvy dosing is 10 mg/kg IV on days 1 and 8 of 21-day cycles, continued until progression or unacceptable toxicity; pembrolizumab schedules follow prescriber determination. Safety requires ...

US FDA approves Keytruda and Keytruda Qlex, each with Trodelvy as first-line treatment of PD-L1+ (CPS =10) advanced TNBC: Rahway, New Jersey Friday, June 26, 2026, 09:00 Hrs [IST] ...

The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co Inc.’s (NYSE:MRK) Keytruda (pembrolizumab) for adult patients with resectable locally advanced head and neck squamous cell ...

(RTTNews) - Merck & Co Inc. (MRK) on Wednesday said the U.S. Food and Drug Administration has approved Keytruda and Keytruda Qlx, a subcutaneous formulation of Keytruda, in combination with paclitaxel ...

Merck has obtained the Food and Drug Administration’s permission for Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, for the treatment of adult patients with resectable locally advanced head and ...

Keytruda Qlex must be administered by a health care provider. The Food and Drug Administration (FDA) has approved Keytruda Qlex ™ (pembrolizumab and berahyaluronidase alfa-pmph) for patients aged 12 ...

Keytruda is approved for resectable locally advanced head and neck squamous cell carcinoma with PD-L1 expression, marking a significant advancement in treatment options. The KEYNOTE-689 trial showed a ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

The approval is based on results from the KEYNOTE-905/EV-303 trial, conducted in partnership with Pfizer and Astellas.

The U.S. Food and Drug Administration has granted approval to Merck & Co. (NYSE:MRK) for the use of KEYTRUDA and KEYTRUDA QLEX, in combination with paclitaxel, with or without bevacizumab, to treat ...